Premium
Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma
Author(s) -
Van Den Berge M.,
Luijk B.,
Bareille P.,
Dallow N.,
Postma D. S.,
Lammers J. W. J.
Publication year - 2010
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/j.1398-9995.2010.02414.x
Subject(s) - fluticasone propionate , medicine , placebo , asthma , fluticasone , corticosteroid , crossover study , allergy , inhalation , exhaled nitric oxide , endocrinology , anesthesia , pharmacology , immunology , alternative medicine , pathology , bronchoconstriction
To cite this article: van den Berge M, Luijk B, Bareille P, Dallow N, Postma DS, Lammers J‐WJ. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy 2010; 65 : 1531–1535. Abstract Introduction: Single‐dose inhaled corticosteroids (ICS) induce direct anti‐inflammatory effects in asthma thereby improving airway hyperresponsiveness (AHR). A novel enhanced‐affinity ICS, fluticasone furoate (FF), demonstrated a prolonged duration of action in vitro . The aim of this study was to evaluate the efficacy and duration of action of a single dose of FF by studying protection against AHR to adenosine 5′‐monophosphate (AMP) and effects on exhaled nitric oxide (eNO). Methods: A randomized, double‐blind, placebo‐controlled, 6‐way crossover study (FFA10026) was performed in 24 patients with allergic asthma (mean age 32.8 years, FEV 1 ≥ 70% predicted and PC 20 AMP ≤ 50 mg/ml). Each subject received a single dose of FF 1000 μg, fluticasone proprionate (FP) 1000 μg, or placebo at 2 (FF only), 14 or 26 h prior to AMP challenge and eNO measurement. Results: FF significantly improved PC 20 AMP compared to placebo, the difference in doubling concentrations being 2.18 (95% confidence interval: 1.13–3.23), 1.54 (0.48–2.59), and 1.30 (0.26–2.34) at 2, 14 and 26 h. FP improved PC 20 AMP significantly at 14 h compared to placebo, but not at the 26‐hour time point, the difference in doubling concentrations being 1.72 (0.70–2.75) and 0.33 (−0.69–1.34). There was no significant effect on eNO after either FF or FP at all time points. FF was well tolerated and there were no serious adverse events. Conclusion: The new inhaled corticosteroid FF, but not FP, demonstrates prolonged protection up to 26 h against AHR to AMP in asthma patients.